Sermorelin + Ipamorelin Blend is supplied as one laboratory research vial containing Sermorelin 5mg and Ipamorelin 5mg, for 10mg combined nominal content. The component amounts describe the listed material rather than a human dose or prepared solution concentration. The illustrated 3ml marking refers to container capacity.
Sermorelin is retained as its own component name rather than being relabeled CJC-1295. The two-ingredient listing specifies a 10mg combined nominal content. The gland-and-signal illustration organizes the research subject visually; it does not show a measured biological response or promise a growth-hormone outcome.
GHRH(1-29) structure-activity experiments measured GH release. Ipamorelin has separate preclinical receptor evidence, not a trial of this finished blend. The references below explain the specific study context. No direct study of this exact supplied blend was identified in this review. Comparisons should distinguish individual-component evidence from mixture-specific stability, interactions and biological activity; a source link is not an endorsement or batch certification.
Match the product designation, individual component identities and stated amounts against the relevant analytical report before drawing laboratory conclusions. The SRP research chart is explanatory, and the COA, chromatography, mass-spectrometry and traceability illustrations are educational examples, not test results for this vial. For laboratory research only; not for human or veterinary use, diagnosis or treatment.
Reviews
There are no reviews yet.